NovoCure Crecimiento futuro

Future controles de criterios 1/6

Se prevé un crecimiento anual de los beneficios y los ingresos de NovoCure de 2.1% y 9.8% por año respectivamente. Se prevé que el BPA crezca en un 4.4% al año. Se espera que la rentabilidad financiera sea de -420.1% en 3 años.

Información clave

5.1%

Tasa de crecimiento de los beneficios

6.1%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Medical Equipment	16.5%
Tasa de crecimiento de los ingresos	9.1%
Rentabilidad financiera futura	-218.9%
Cobertura de analistas	Good
Última actualización	07 May 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Some Shareholders Feeling Restless Over NovoCure Limited's (NASDAQ:NVCR) P/S Ratio

Mar 03

NovoCure: Stay Cautious Amid Positive Signs

Jan 19

Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

Nov 16

Is NovoCure (NASDAQ:NVCR) Weighed On By Its Debt Load?

Aug 13

Is NovoCure (NASDAQ:NVCR) A Risky Investment?

May 15

A Look At The Intrinsic Value Of NovoCure Limited (NASDAQ:NVCR)

Apr 24

Why NovoCure Limited (NASDAQ:NVCR) Could Be Worth Watching

Feb 10

Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

Jan 16

NovoCure: See Past Market Myopia And Buy The Dip

Sep 27

Novocure creates new CNS focused franchise to renew growth in brain cancer business

Sep 21

Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

Sep 09

NovoCure: Does The Reward Outweigh The Risk? I Believe So

Sep 09

NovoCure Q2 2022 Earnings Preview

Jul 27

Is NovoCure (NASDAQ:NVCR) Using Too Much Debt?

May 28

NovoCure: A Stalwart With More Upsides

May 09

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:NVCR - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	665	-187	-105	N/A	6
12/31/2025	587	-193	-111	-143	7
12/31/2024	551	-174	-106	-143	6
3/31/2024	526	-193	-121	-88	N/A
12/31/2023	509	-207	-100	-73	N/A
9/30/2023	504	-197	-89	-62	N/A
6/30/2023	508	-174	-46	-21	N/A
3/31/2023	522	-141	-5	18	N/A
12/31/2022	538	-93	9	31	N/A
9/30/2022	543	-82	20	49	N/A
6/30/2022	545	-68	24	51	N/A
3/31/2022	538	-59	36	61	N/A
12/31/2021	535	-58	59	83	N/A
9/30/2021	546	-27	106	122	N/A
6/30/2021	545	-5	113	128	N/A
3/31/2021	527	12	99	115	N/A
12/31/2020	494	20	84	99	N/A
9/30/2020	450	19	40	53	N/A
6/30/2020	409	12	24	37	N/A
3/31/2020	380	9	22	33	N/A
12/31/2019	351	-7	16	27	N/A
9/30/2019	322	-27	27	36	N/A
6/30/2019	294	-41	19	27	N/A
3/31/2019	269	-55	4	11	N/A
12/31/2018	248	-64	-9	-2	N/A
9/30/2018	232	-59	-28	-22	N/A
6/30/2018	217	-59	-32	-25	N/A
3/31/2018	194	-64	-30	-23	N/A
12/31/2017	177	-62	N/A	-33	N/A
9/30/2017	154	-73	N/A	-44	N/A
6/30/2017	125	-95	N/A	-80	N/A
3/31/2017	105	-114	N/A	-104	N/A
12/31/2016	83	-132	N/A	-108	N/A
9/30/2016	65	-143	N/A	-120	N/A
6/30/2016	52	-135	N/A	-109	N/A
3/31/2016	41	-124	N/A	-102	N/A
12/31/2015	33	-112	N/A	-100	N/A
9/30/2015	25	-102	N/A	-91	N/A
6/30/2015	20	-94	N/A	-87	N/A
3/31/2015	18	-86	N/A	-83	N/A
12/31/2014	15	-81	N/A	-74	N/A
12/31/2013	10	-77	N/A	-53	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que NVCR siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que NVCR siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que NVCR siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (9.2% al año) de NVCR crezcan más rápidamente que los del mercado US (8.2% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 9.8% al año) de NVCR crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: NVCR se prevé que no sea rentable en 3 años.

NovoCure Crecimiento futuro

Future controles de criterios 1/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target increased by 8.8% to US$27.20

Price target decreased by 42% to US$35.17

Price target decreased by 9.4% to US$60.33

Price target decreased by 16% to US$64.17

Consensus EPS estimates fall by 31%

Price target decreased by 20% to US$82.00

Recent updates

NovoCure Limited announced that it expects to receive $400 million in funding

NovoCure Limited Q1 Earnings: Core Business Accelerating

NovoCure Limited announced that it expects to receive $400 million in funding

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

NovoCure Limited Announces Results of the Metis Phase 3 Clinical Trial in Brain Metastases from Non-Small Cell Lung Cancer

NovoCure Limited, Annual General Meeting, Jun 05, 2024

New minor risk - Insider selling

New minor risk - Shareholder dilution

NovoCure (NASDAQ:NVCR) Has Debt But No Earnings; Should You Worry?

NovoCure Limited to Report Q1, 2024 Results on May 02, 2024

NovoCure: Sell The METIS-Inspired Rally

Price target increased by 8.8% to US$27.20

Some Shareholders Feeling Restless Over NovoCure Limited's (NASDAQ:NVCR) P/S Ratio

Full year 2023 earnings: EPS exceeds analyst expectations

NovoCure: Stay Cautious Amid Positive Signs

Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer

NovoCure Limited Announces Last Patient Enrolled in Phase 3 Trident Trial in Newly Diagnosed Glioblastoma

NovoCure Limited Announces Executive Changes

Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-Term Growth Drivers and an Accelerated Path to Profitability

Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

Chief Financial Officer exercised options to buy US$231k worth of stock.

Third quarter 2023 earnings released: US$0.46 loss per share (vs US$0.25 loss in 3Q 2022)

NovoCure Limited to Report Q3, 2023 Results on Oct 26, 2023

NovoCure Limited(NasdaqGS:NVCR) dropped from FTSE All-World Index (USD)

Novocure Announces the Lancet Oncology Publishes Primary Data from Phase 3 Lunar Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

Price target decreased by 42% to US$35.17

Is NovoCure (NASDAQ:NVCR) Weighed On By Its Debt Load?

Price target decreased by 9.4% to US$60.33

Levi & Korsinsky Notifies NovoCure Limited Investors of a Class Action Lawsuit and Upcoming Deadline

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Novocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 Panova-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer

NovoCure Limited to Report Q2, 2023 Results on Jul 27, 2023

Holzer & Holzer, LLC Files Lawsuit Against NovoCure Limited

Price target decreased by 16% to US$64.17

Zai Lab and Novocure Announces Lunar Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

Is NovoCure (NASDAQ:NVCR) A Risky Investment?

Consensus EPS estimates fall by 31%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 20% to US$82.00

A Look At The Intrinsic Value Of NovoCure Limited (NASDAQ:NVCR)

Consensus EPS estimates fall by 12%

Chief Operating Officer notifies of intention to sell stock

Chief Operating Officer recently sold US$165k worth of stock

Consensus EPS estimates fall by 31%

Full year 2022 earnings released: US$0.88 loss per share (vs US$0.56 loss in FY 2021)

Novocure Announces Last Patient Enrolled in Pivotal PANOVA-3 Study of Tumor Treating Fields in Pancreatic Cancer

Why NovoCure Limited (NASDAQ:NVCR) Could Be Worth Watching

Novocure Announces Executive Changes

Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

President notifies of intention to sell stock

Zai Lab Limited and Novocure Announce Pivotal Lunar Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint

Price target increased to US$98.86

Insufficient new directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Novocure Announces 11 Presentations on Tumor Treating Fields in Multiple Solid Tumor Types at the American Society for Radiation Oncology 2022 Annual Meeting

Chief Development Officer notifies of intention to sell stock

Chief Development Officer notifies of intention to sell stock

Chief Development Officer notifies of intention to sell stock

NovoCure Limited to Report Q3, 2022 Results on Oct 27, 2022

NovoCure: See Past Market Myopia And Buy The Dip

Chief Development Officer notifies of intention to sell stock

Novocure creates new CNS focused franchise to renew growth in brain cancer business

Chief Development Officer notifies of intention to sell stock

Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

NovoCure: Does The Reward Outweigh The Risk? I Believe So

Chief Financial Officer recently sold US$70k worth of stock

Executive Chairman recently sold US$58k worth of stock

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind